Related Experiment Video

Updated: Aug 14, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

[Somatostatin receptors--new diagnostic and therapeutic possibilities]

Marek Pawlikowski

    Endokrynologia Polska
    |December 13, 2005
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
    10:28

    Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

    Published on: January 22, 2018

    Related Experiment Videos

    Last Updated: Aug 14, 2026

    A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
    08:55

    A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

    Published on: April 17, 2019

    Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
    10:28

    Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

    Published on: January 22, 2018

    Related Concept Videos

    Transducer Mechanism: Enzyme-Linked Receptors01:27

    Transducer Mechanism: Enzyme-Linked Receptors

    Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
    Major types that are helpful drug targets include:
    Glucagon-like Receptor Agonists01:24

    Glucagon-like Receptor Agonists

    Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
    GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

    Articles linked to this work by shared authors, journal, and citation graph.

    Screen-printed flexible carbon electrodes for efficient neural impulse transmission.

    Scientific reports·2025

    The role of mathematical models in prediction of osteoarthritis development.

    Computers in biology and medicine·2025

    Innovative approach in the treatment of comminuted proximal phalanx fractures in horses based on biomechanical modelling.

    Scientific reports·2025

    Selection of density standard and X-ray tube settings for computed digital absorptiometry in horses using the k-means clustering algorithm.

    BMC veterinary research·2025

    An experimental and theoretical investigation on the hyper-viscoelasticity of polyamide 12 produced by selective laser sintering.

    PloS one·2024

    Comparative analyses of blood flow through mechanical trileaflet and bileaflet aortic valves.

    Acta of bioengineering and biomechanics·2024

    Estimating obesity phenotype features in a real-world cohort - a non-interventional pilot study using an original questionnaire.

    Endokrynologia Polska·2026

    Type 5 diabetes mellitus: revisiting malnutrition-related diabetes.

    Endokrynologia Polska·2026

    Hypophosphatemic rickets in children: current knowledge and a proposal for a diagnostic algorithm.

    Endokrynologia Polska·2026

    Association between Helicobacter pylori infection and hyperandrogenism in women with polycystic ovary syndrome.

    Endokrynologia Polska·2026

    Hematological changes in Cushing's disease from diagnosis to remission: comparison with non-functioning pituitary adenomas.

    Endokrynologia Polska·2026

    Assessment of phenotypes in a unique group of RET proto-oncogene Y791F variant carriers in the Polish population.

    Endokrynologia Polska·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us